Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

Video content above is prompted by the following:

In terms of pneumonitis and cardiotoxicity, is your management and monitoring relatively the same to trastuzumab deruxtecan (T-DXd)?

• What other pertinent adverse effects (AEs) of trastuzumab emtansine (T-DM1) should practicing oncologists be aware of?

1. Peripheral neuropathy
2. Thrombocytopenia
3. Aspartate aminotransferase/alanine aminotransferase elevations

• Let’s dive deeper into managing some of these T-DM1–related AEs; how do you manage the following:

1. Peripheral neuropathy
2. Thrombocytopenia: When do you delay/hold/discontinue therapy?
3. Hepatotoxicity: When do you delay/hold/discontinue therapy?

Please comment on any other treatment-resistant AEs with T-DM1 seen in your clinical practice.